NCT07909837
A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers
At risk: Primary endpoint(s) modified.
See at-risk trials from Nanjing Chia-tai Tianqing Pharmaceutical
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Participants received a single oral dose of NTQ6179 tablets under fasting conditions in 1 of 7 sequential dose cohorts; each cohort comprised 8 participants randomized in a ratio of 6:2 (NTQ6179 : placebo).
Participants received a single oral dose of NTQ6179 placebo tablets under fasting conditions in 1 of 7 sequential dose cohorts; each cohort comprised 8 participants randomized in a ratio of 6:2 (NTQ6179 : placebo).
Drugs: NTQ6179, NTQ6179 placebo
Sites
1 site in 1 country
- Peking Union Medical College Hospital, Chinese Academy of Medical SciencesBeijing, China